MECOM Locus经典转录异型影响瘤免疫微环境和卵巢癌中的不同点
Ning Lan1,2, Shuheng Bai1, Min Chen1,2
1Department of Radiotherapy, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi Province, 710061, PR China.
Journal of ovarian research
|October 19, 2024
概括
这就是MECOM基因.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 免疫学 免疫学 免疫学
背景情况:
- 在高度血清性卵巢癌 (HGSOC) 中,MECOM位点经常被放大.
- 关于MECOM转录在HGSOC预后和瘤免疫微环境 (TIME) 中的作用的研究是有限的.
- 了解MECOM的影响对于HGSOC患者的治疗结果至关重要.
研究的目的:
- 研究MECOM转录表达,患者存活率和HGSOC中的TIME调制之间的关联.
- 确定特定的MECOM异型及其监管作用.
- 探索MECOM作为卵巢癌的潜在治疗点.
主要方法:
- 在352名HGSOC患者和88个正常卵巢组织中分析MECOM转录表达 (GTEx/TCGA数据库).
- 使用生物信息学工具 (UCSC基因组浏览器,Ensembl,NextProt) 来识别MECOM异型.
- 采用了考克斯回归,卡普兰-梅尔曲线和时间评估算法.
- 分析了ChIP-seq和RNA-seq数据,用于监管目标识别.
主要成果:
- 较高的MECOM异形转录与较差的HGSOC存活率相关,可能通过癌症相关纤维细胞 (CAF) 和免疫抑制细胞.
- 较高的EVI1异形转录与改善的生存率有关,与CD8+T细胞,巨细胞和减少的JUN活性有关.
- MECOM异构体对卵巢癌存活率和瘤发育有不同的影响.
结论:
- 在HGSOC病原和患者预后中,MECOM异型具有不同的作用.
- 针对MECOM拼接变体可能为卵巢癌提供新的治疗策略.
- 进一步研究MECOM的分子机制对于药物开发至关重要.
相关概念视频
MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
Induced Pluripotent Stem Cells
3.9K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
3.9K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K


